Dupont Capital Management Corp acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,440 shares of the pharmaceutical company’s stock, valued at approximately $186,000.

Several other institutional investors also recently modified their holdings of VRTX. First Manhattan Co. raised its position in shares of Vertex Pharmaceuticals by 1.3% in the first quarter. First Manhattan Co. now owns 2,356 shares of the pharmaceutical company’s stock valued at $205,000 after buying an additional 31 shares during the last quarter. Korea Investment CORP raised its position in shares of Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock valued at $104,000 after buying an additional 658 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of Vertex Pharmaceuticals by 0.9% in the first quarter. Fisher Asset Management LLC now owns 5,213 shares of the pharmaceutical company’s stock valued at $570,000 after buying an additional 45 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Vertex Pharmaceuticals by 32.1% in the first quarter. Russell Investments Group Ltd. now owns 96,922 shares of the pharmaceutical company’s stock valued at $10,600,000 after buying an additional 23,528 shares during the last quarter. Finally, Wetherby Asset Management Inc. bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at $348,000. 92.87% of the stock is currently owned by institutional investors.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 156.29 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The firm has a market capitalization of $39.40 billion, a P/E ratio of 150.13 and a beta of 1.77. The stock has a 50 day moving average of $149.67 and a 200-day moving average of $120.19.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The business had revenue of $544.10 million for the quarter, compared to the consensus estimate of $489.95 million. During the same quarter in the previous year, the company posted $0.24 EPS. The company’s revenue was up 26.1% compared to the same quarter last year. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/31/dupont-capital-management-corp-purchases-new-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Several equities analysts have recently weighed in on VRTX shares. Vetr raised shares of Vertex Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $102.09 price objective on the stock in a research report on Monday, May 15th. Morgan Stanley reissued an “overweight” rating and issued a $153.00 price objective (up from $150.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Bank of America Corporation reissued a “neutral” rating and issued a $125.00 price objective (up from $121.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. JMP Securities reissued an “outperform” rating and issued a $127.00 price objective (up from $125.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Finally, UBS AG reissued a “buy” rating and issued a $135.00 price objective (up from $132.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Six equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $162.88.

In other news, CEO Jeffrey M. Leiden sold 216,624 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $160.96, for a total transaction of $34,867,799.04. Following the transaction, the chief executive officer now owns 400,266 shares of the company’s stock, valued at approximately $64,426,815.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Ian F. Smith sold 4,250 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $155.39, for a total value of $660,407.50. Following the transaction, the chief financial officer now directly owns 120,138 shares in the company, valued at approximately $18,668,243.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 751,042 shares of company stock worth $113,078,257. Corporate insiders own 1.80% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.